《bicyclam衍生物JM3100的高效和有选择性的抗HIV活性》

  • 来源专题:艾滋病防治
  • 编译者: 李越
  • 发布时间:2005-04-17
  • Bicyclams, in which the cyclam (1,4,8,11-tetraazacyclotetradecane) moieties are tethered via an aliphatic bridge (i.e., propylene, as in JM2763) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) (E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. Thornton, G. Bridger, S. Fricker, G. Henson, M. Abrams, and D. Picker, Proc. Natl. Acad. Sci. USA 89:5286-5290, 1992). We have now found that the bicyclam JM3100, in which the cyclam moieties are tethered by an aromatic bridge [i.e., phenylenebis(methylene)], inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines at a 50% effective concentration (EC50) of 1 to 10 ng/ml, which is about 100-fold lower than the concentration required for JM2763 to inhibit HIV replication and at least 100,000-fold lower than the cytotoxic concentration (> 500 micrograms/ml). In primary T4 lymphocytes or primary monocytes, JM3100 proved inhibitory to HIV-1(IIIB) and several clinical HIV-1 isolates at an EC50 of less than 1 ng/ml. On the basis of time-of-addition experiments, JM3100 appeared to interact with a viral uncoating event, and this was further corroborated by an uncoating assay in which RNase sensitivity of [5-3H]uridine-labeled virions was monitored. In addition, but possibly mechanistically related, JM3100 blocks formation of infectious particles. JM3100 was also found to interfere directly with virus-induced syncytium formation, albeit at a higher concentration (1 to 2 microgram/ml) than that required for inhibition of viral replication. Following subcutaneous injection of 10 mg of JM3100 per kg of body weight to rabbits, anti-HIV activity was detected in serum corresponding to serum drug levels exceeding for at least 6 h by >100-fold the EC(50) required to inhibit HIV replication in vitro. When combined with either 3'-azido-2',3' -dideoxythymidine or 2',3' -dideoxyinosine, JM3100 achieved a additive inhibition of HIV replication, and when repeatedly subcultivated in the presence of JM3100, the virus remained sensitive to the compound for at least 30 passages (120 days) in cell culture.
  • 原文来源:http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=284523
相关报告
  • 《具抗HIV活性的联苯酮醛衍生物》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2006-10-17
    • 专利申请号01806956.8,该专利已被中国国家知识产权局授权。 摘要: xenaldial、xenalemine和xenalic acid在治疗HIV感染和相关疾病,尤其是AIDS中的用途。本发明还涉及组合制剂形式的药物组合物,其包含选自xenaldial、xenalamine和xenalic acid的化合物以及至少一种选自蛋白酶抑制剂、逆转录酶抑制剂和整合酶抑制剂的抗HIV药剂。 权利要求书 1.选自xenalamine、xenalic acid和xenaldial的化合物的用途,其用于制备治疗HIV感染的药物。
  • 《显示杀精子活性和抗病毒活性的AZT衍生物 申请(专利)号:99806505.6》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-03-18
    • 用包含显示杀精子活性或使精子活动抑制活性的基于嘧啶碱基的核苷或核苷酸的避孕组合物,既能提供避孕活性,又能提供抗病毒的防护。在一个实施例中,该活性成分包含一有5-卤、6-烷氧基取代的胸腺嘧啶环(例如AZT)。通过提供具有磷酸芳基酯取代的AZT的戊糖环,观察到某些AZT衍生物在抗HIV活性方面的额外改进。